United Therapeutics Issues its 2023 Corporate Responsibility and Public Benefit Report
12 Setembro 2023 - 7:00AM
Business Wire
Report available at corporateresponsibility.unither.com
United Therapeutics Corporation (Nasdaq: UTHR), a public
benefit corporation (PBC), today announced the release of
its 2023 Corporate Responsibility and Public Benefit Report
covering its 2022 progress toward its public benefit goals and
objectives and summarizing its efforts to advance the interests of
its patients and other stakeholders.
As a PBC, United Therapeutics is obligated to report its
progress toward its public benefit purpose — to provide a brighter
future for patients through the development of novel pharmaceutical
therapies, and technologies that expand the availability of
transplantable organs. It pursues this purpose alongside its
obligations to balance the interests of its other stakeholders,
including employees, local communities, investors, and the greater
ecosystem in which it operates. This is the first full year United
Therapeutics is reporting its progress against its public benefit
goals and objectives established in 2021, aligned with its three
core stakeholder groups — what the company calls Our Patients, Our
People, and Humankind.
The company reported that as of the end of 2022, it was serving
more than 12,500 patients on its therapies. “Patient outcomes are
our top priority,” said James Edgemond, Chief Financial
Officer and Treasurer of United Therapeutics. “We also know patient
outcomes are inextricably linked to the other domains of our PBC
goals. For example, we need smart, committed, passionate people to
do this work, and we need to steward our resources — human,
financial, and environmental — to get better, long-lasting
outcomes.”
Underscoring this point, some of the progress metrics United
Therapeutics reports include very low voluntary turnover — 9%
compared to an almost-15% industry average — and the opening of a
first of its -kind site net zero cold storage current Good
Manufacturing Practices warehouse in North Carolina in 2023. This
is the fifth site net zero facility in the company’s portfolio,
which altogether represent about 16% of the portfolio’s square
footage.
“We have taken what we know are leading actions in terms of the
environmental footprint of our facilities,” said Christopher
Causey, Chair of the Nominating and Governance Committee of the
United Therapeutics Board of Directors. “And still, as our CEO Dr.
Martine Rothblatt says in her opening message of the report,
we understand there is more work ahead. We are committed to taking
meaningful, evidence-based actions that we look forward to sharing
with our stakeholders as we continue forward.”
Find the full report at corporateresponsibility.unither.com.
United Therapeutics: Enabling Inspiration
At United Therapeutics, our vision and mission are one. We use
our enthusiasm, creativity, and persistence to innovate for the
unmet medical needs of our patients and to benefit our other
stakeholders. We are bold and unconventional. We have fun; we do
good. We are the first publicly traded biotech or pharmaceutical
company to take the form of a public benefit corporation. Our
public benefit purpose is to provide a brighter future for patients
through (a) the development of novel pharmaceutical therapies; and
(b) technologies that expand the availability of transplantable
organs.
You can learn more about what it means to be a PBC here:
unither.com/PBC.
Forward-looking Statements
Statements included in this press release that are not
historical in nature are “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include, among others, statements
regarding progress toward achieving our public benefit purpose and
the interests of other stakeholders (including employees, local
communities, investors, and the greater ecosystem in which we
operate), our efforts to steward our resources — human, financial,
and environmental — to get better, long-lasting outcomes, our
commitment to taking meaningful, evidence-based actions, and our
goals of innovating for the unmet medical needs of our patients and
to benefit our other stakeholders and furthering our public benefit
purpose of developing novel pharmaceutical therapies and
technologies that expand the availability of transplantable organs.
These forward-looking statements are subject to certain risks and
uncertainties, such as those described in our periodic reports
filed with the Securities and Exchange Commission, that could cause
actual results to differ materially from anticipated results.
Consequently, such forward-looking statements are qualified by the
cautionary statements, cautionary language and risk factors set
forth in our periodic reports and documents filed with the
Securities and Exchange Commission, including our most recent
Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and
Current Reports on Form 8-K. We claim the protection of the safe
harbor contained in the Private Securities Litigation Reform Act of
1995 for forward-looking statements. We are providing this
information as of September 12, 2023, and assume no obligation to
update or revise the information contained in this press release
whether as a result of new information, future events, or any other
reason.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230912165759/en/
Catherine Sheehy at (240) 398-3504 (sustainability) Dewey
Steadman at (202) 919-4097 (investors/media)
United Therapeutics (NASDAQ:UTHR)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
United Therapeutics (NASDAQ:UTHR)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024